Browsing by Author The Genomics Institute of the Novartis Research Foundation

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)
1-Jan-2014KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmissionKelli L. Kuhen; Arnab K. Chatterjee; Matthias Rottmann; Kerstin Gagaring; Rachel Borboa; Jennifer Buenviaje; Zhong Chen; Carolyn Francek; Tao Wu; Advait Nagle; S. Whitney Barnes; David Plouffe; Marcus C.S. Lee; David A. Fidock; Wouter Graumans; Marga Van De Vegte-Bolmer; Geert J. Van Gemert; Grennady Wirjanata; Boni Sebayang; Jutta Marfurt; Bruce Russell; Rossarin Suwanarusk; Ric N. Price; Francois Nosten; Anchalee Tungtaeng; Montip Gettayacamin; Jetsumon Sattabongkot; Jennifer Taylor; John R. Walker; David Tully; Kailash P. Patra; Erika L. Flannery; Joseph M. Vinetz; Laurent Renia; Robert W. Sauerwein; Elizabeth A. Winzeler; Richard J. Glynne; Thierry T. Diagana; The Genomics Institute of the Novartis Research Foundation; Swiss Tropical and Public Health Institute (Swiss TPH); Universitat Basel; Columbia University, College of Physicians and Surgeons; Radboud University Nijmegen Medical Centre; Menzies School of Health Research; Eijkman Institute for Molecular Biology; Agency for Science, Technology and Research, Singapore; Shoklo Malaria Research Unit; Mahidol University; Nuffield Department of Clinical Medicine; Armed Forces Research Institute of Medical Sciences, Thailand; University of California, San Diego; University of California, San Diego, School of Medicine; Novartis Institute for Tropical Diseases Pte. Ltd.; California Institute for Biomedical Research
7-Dec-2018Open-source discovery of chemical leads for next-generation chemoprotective antimalarialsYevgeniya Antonova-Koch; Stephan Meister; Matthew Abraham; Madeline R. Luth; Sabine Ottilie; Amanda K. Lukens; Tomoyo Sakata-Kato; Manu Vanaerschot; Edward Owen; Juan Carlos Jado Rodriguez; Steven P. Maher; Jaeson Calla; David Plouffe; Yang Zhong; Kaisheng Chen; Victor Chaumeau; Amy J. Conway; Case W. McNamara; Maureen Ibanez; Kerstin Gagaring; Fernando Neria Serrano; Korina Eribez; Cullin Mc Lean Taggard; Andrea L. Cheung; Christie Lincoln; Biniam Ambachew; Melanie Rouillier; Dionicio Siegel; François Nosten; Dennis E. Kyle; Francisco Javier Gamo; Yingyao Zhou; Manuel Llinás; David A. Fidock; Dyann F. Wirth; Jeremy Burrows; Brice Campo; Elizabeth A. Winzeler; GlaxoSmithKline plc, Spain; Harvard School of Public Health; University of California, San Diego; The University of Georgia; Columbia University Medical Center; University of California, San Diego, School of Medicine; Mahidol University; The Genomics Institute of the Novartis Research Foundation; Nuffield Department of Clinical Medicine; University of South Florida, Tampa; Pennsylvania State University; Broad Institute; BioSero; California Institute for Biomedical Research; Medicines for Malaria Venture
3-Sep-2010Spiroindolones, a potent compound class for the treatment of malariaMatthias Rottmann; Case McNamara; Bryan K.S. Yeung; Marcus C.S. Lee; Bin Zou; Bruce Russell; Patrick Seitz; David M. Plouffe; Neekesh V. Dharia; Jocelyn Tan; Steven B. Cohen; Kathryn R. Spencer; Gonzalo E. González-Páez; Suresh B. Lakshminarayana; Anne Goh; Rossarin Suwanarusk; Timothy Jegla; Esther K. Schmitt; Hans Peter Beck; Reto Brun; Francois Nosten; Laurent Renia; Veronique Dartois; Thomas H. Keller; David A. Fidock; Elizabeth A. Winzeler; Thierry T. Diagana; Swiss Tropical and Public Health Institute (Swiss TPH); Universitat Basel; The Genomics Institute of the Novartis Research Foundation; Novartis Institute for Tropical Diseases Pte. Ltd.; Columbia University Medical Center; Agency for Science, Technology and Research, Singapore; National University of Singapore; Scripps Research Institute; Pennsylvania State University; Novartis International AG; Shoklo Malaria Research Unit; Mahidol University; Nuffield Department of Clinical Medicine
29-Nov-2013Targeting Plasmodium PI(4)K to eliminate malariaCase W. McNamara; Marcus C.S. Lee; Chek Shik Lim; Siau Hoi Lim; Jason Roland; Advait Nagle; Oliver Simon; Bryan K.S. Yeung; Arnab K. Chatterjee; Susan L. McCormack; Micah J. Manary; Anne Marie Zeeman; Koen J. Dechering; T. R.Santha Kumar; Philipp P. Henrich; Kerstin Gagaring; Maureen Ibanez; Nobutaka Kato; Kelli L. Kuhen; Christoph Fischli; Matthias Rottmann; David M. Plouffe; Badry Bursulaya; Stephan Meister; Lucia Rameh; Joerg Trappe; Dorothea Haasen; Martijn Timmerman; Robert W. Sauerwein; Rossarin Suwanarusk; Bruce Russell; Laurent Renia; Francois Nosten; David C. Tully; Clemens H.M. Kocken; Richard J. Glynne; Christophe Bodenreider; David A. Fidock; Thierry T. Diagana; Elizabeth A. Winzeler; The Genomics Institute of the Novartis Research Foundation; Columbia University Medical Center; Novartis Institutes for Tropical Disease; University of California, San Diego; Biomedical Primate Research Centre - Rijswijk; TropIQ Health Sciences; Swiss Tropical and Public Health Institute (Swiss TPH); Universitat Basel; Boston University School of Medicine; Novartis International AG; Radboud University Nijmegen Medical Centre; Agency for Science, Technology and Research, Singapore; Yong Loo Lin School of Medicine; Nuffield Department of Clinical Medicine; Mahidol University